# Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma

> **NCT06304350** · PHASE2 · RECRUITING · sponsor: **Tongji University** · enrollment: 25 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Combination of pembrolizumab and platinum containing dual drugs

## Key facts

- **NCT ID:** NCT06304350
- **Lead sponsor:** Tongji University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-17
- **Primary completion:** 2026-02-25
- **Final completion:** 2026-12-31
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2024-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06304350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06304350, "Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06304350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*